Calea Modern Slavery Act 2015 statement


Modern Slavery statement for Fresenius Kabi Limited and Calea UK Limited

1. Introduction

This statement is made pursuant to section 54 of the UK Modern Slavery Act 2015 to set out the steps that FHC Holdings Limited and its subsidiaries (Calea UK Limited and Fresenius Kabi Limited) have taken during the previous financial year to ensure that modern slavery is not taking place in its business or supply chain.

This statement reflects activity carried out in the financial year up to and including 31 December 2020. This statement has been approved by the Management Board on 30th June 2021.

2. Organisation and supply chain

2.1 Our organisation

Fresenius Kabi is a global healthcare company that specialises in developing, producing and marketing pharmaceuticals and medical devices for the therapy and care for critically and chronically ill patients worldwide. Our products are vital in the treatment in hospital and outpatient care.

We’re part of the Fresenius healthcare group and our ultimate parent is Fresenius SE & Co KGaA (Fresenius Group).

2.2 Our supply chain

Our responsibility as a healthcare group goes beyond our business operations. Responsible and sustainable management is an integral part of our culture and our daily business.

More than 80% of the products that we buy are purchased from within the Fresenius Group. The remainder of the products are sourced from third-party providers who are mainly located in the UK.

3. Due diligence processes and risk assessment

Our aim is to conduct business with individuals and organisations who share our commitment to the highest ethical standards and share common principles of social accountability.

We carry out due diligence checks on suppliers relating to the labour standards within the supply chain of the products and services they supply to us including a Corporate Social Responsibility questionnaire.

Our suppliers are expected to comply with all applicable national and international laws and regulations with the requirements and standards set out in the Fresenius Kabi Supplier Code of Conduct Business conduct and ethics which can be found out at .

We include obligations in agreements with our key suppliers (for it and its supply chain) to comply with the requirements of the Modern Slavery Act and our Code of Conduct. If we become aware of any actions or conditions within supply chains that are not in compliance with the Code, we reserve the right to demand corrective action measures and to terminate agreements with any supplier who does not comply with these requirements.

4. Training for staff

Everyone who works at Fresenius receives training on our Group Code of Conduct which includes compliance with laws and a prohibition to agreeing to, using or supporting compulsory or illegal child labour. E-learning on our Code of Conduct is carried out by our staff. This is mandatory e-learning is repeated every 2 years.

In 2018, we introduced the Code of Conduct training as a part of our induction for all new starters.

5. Measuring effectiveness

We will be assessing the effectiveness of our measures by reviewing:

  • If there are any reports to our Compliance Hotline and/or Compliance Team; and
  • Feedback from our Supply Chain team

Next Steps

Over the next 12 months, we will continue to improve and refine our approach to modern slavery including:

  • Assessing the need for further policies and procedures
  • Extending our due diligence exercise to further suppliers
  • Including detailed provisions relating to anti-slavery and human trafficking in all contracts with suppliers
  • Continue to provide training to our people as well as include key points on modern slavery in our Compliance Matters bulletin which is available to all staff

Our next statement will follow the year ending 31 December 2021.


Position: Managing Director

Date: 30 June 2021


HPN and Immunotherapy Homecare team call: 0800 121 8300
Biosimilars Homecare team call: 0800 090 2461